Results 81 to 90 of about 271,655 (296)

Latent membrane protein 1 (LMP1) expression in Hodgkin lymphoma and its correlation with clinical and histologic parameters

World Journal of Surgical Oncology, 2017
Background Hodgkin lymphoma is one of the most prevalent lymphoproliferative disorders in Pakistan; however, no risk factors for this disease have yet to be established in our population.
Atif Ali Hashmi, Zubaida Fida Hussain, Kashif Ali Hashmi, Muhammad Irfan Zafar, Muhammad Muzzammil Edhi, Naveen Faridi, Mehmood Khan   +6 more
doaj   +1 more source

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness [PDF]

, 2010
Firas Badin, John HayslipUniversity of Kentucky, Markey Cancer Center, Lexington, KY, USAAbstract: Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma. In this paper we review recent
Firas Badin, Hayslip, John, Badin, Firas, John Hayslip   +3 more
core   +1 more source

Relationship between continuous infusion meropenem PK/PD target attainment and C‐reactive protein dynamics in onco‐haematologic patients with febrile neutropenia

British Journal of Clinical Pharmacology, EarlyView.
Aim Meropenem is a second‐line antimicrobial agent in the treatment of febrile neutropenia in onco‐haematological patients. A population pharmacokinetic/pharmacodynamic (PK/PD) analysis for assessing the relationship between meropenem exposure and C‐reactive protein (C‐RP) over time was conducted.
Chun Liu, Pier Giorgio Cojutti, J. G. Coen van Hasselt, Michele Bartoletti, Maddalena Giannella, Pierluigi Zinzani, Pierluigi Viale, Federico Pea   +7 more
wiley   +1 more source

Treatment-refractory non-Hodgkin lymphoma of the prostate: A case report and review of the literature

Urology Case Reports, 2019
Non-Hodgkin lymphoma of the prostate is uncommon. Prostate specific antigen and transrectal ultrasound do not aid in diagnosis. Survival and treatment options are ultimately based on immune-histologic subtype and stage.
Alex Galante, Ruth Jaya Asirvatham, Lawrence L. Yeung   +2 more
doaj   +1 more source

Non-Hodgkin’s lymphoma [PDF]

Clinical Medicine, 2001
Le lymphome non-Hodgkinien est decrit ainsi que sa classification, les facteurs de pronostic de survie, les criteres cliniques de diagnostic et les nouvelles approches ...
openaire   +2 more sources

Composite Lymphoma: EBV-positive Classic Hodgkin Lymphoma and Peripheral T-cell Lymphoma A Case Report

, 2009
Composite lymphomas are rare and defined as hematopoietic neoplasms with more than I malignant lymphomatous clone showing different phenotypic features.
Berg, Anke Van Den, Weiss, Lawrence M., Bacchi, Carlos E., Van Den Berg, Anke; id_orcid, Gualco, Gabriela, Van Den Berg, Anke, Chioato, Lucimara   +6 more
core   +1 more source

Utilization of immune checkpoint inhibitors for the treatment of cancer in Scotland, 2018–2024: A national retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of the study is to describe the use of immune checkpoint inhibitors (ICIs) for the treatment of cancer in Scotland. Methods The retrospective observational cohort study included patients aged 18 years or older who commenced treatment with an ICI in Scotland between 1 January 2018 and 31 December 2024.
Tanja Mueller, Christine Crearie, Liya Lu, Jiafeng Pan, Fraser N. Sneden, David Martin, Amanj Kurdi, Catherine S. Thomson, Julie Clarke, Marion Bennie   +9 more
wiley   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Association of HHV-6 with Hodgkin and non Hodgkin lymphoma

Iranian Journal of Microbiology, 2016
Background and Objectives: Human Herpes 6 virus (HHV-6) could remain latent and chronic in the host cells after primary infection. HHV-6 genome encodes certain trans activation proteins which may results in development of malignantlymphoma.
Hadis Kiani, Manoochehr Makvandi, Alireza Samarbafzadeh, Ali Teimoori, Niloofar Neisi, Hamideh Mehravaran, Hashem Radmehr, Zeinab Hosseini, Azadeh Haghi, Toran Shahani, Mehran Varnaseri, Nastaran Ranjbari   +11 more
doaj  

Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphoma

British Journal of Clinical Pharmacology, EarlyView.
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng, Zhiling Yu, Mark Kaplan, Argyrios Gkasiamis, Akshay Sudhindra, Li Zhu, Manisha Lamba, Fan Wu   +7 more
wiley   +1 more source